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Abstract Congenital abnormalities of the kidney and
urinary tract are frequently observed in children and
represent a significant cause of morbidity and mortality.
These conditions are phenotypically variable, often affect-
ing several segments of the urinary tract simultaneously,
making clinical classification and diagnosis difficult. Renal
agenesis/hypoplasia and dysplasia account for a significant
portion of these anomalies, and a genetic contribution to its
cause is being increasingly recognized. Nevertheless,
overlap between diseases and challenges in clinical diag-
nosis complicate studies attempting to discover new genes
underlying this anomaly. Most of the insights in kidney
development derive from studies in mouse models or from
rare, syndromic forms of human developmental disorders of
the kidney and urinary tract. The genes implicated have
been shown to regulate the reciprocal induction between the
ureteric bud and the metanephric mesenchyme. Strategies
to find genes causing renal agenesis/hypoplasia and
dysplasia vary depending on the characteristics of the study
population available. The approaches range from candidate
gene association or resequencing studies to traditional
linkage studies, using outbred pedigrees or genetic isolates,
to search for structural variation in the genome. Each of
these strategies has advantages and pitfalls and some have
led to significant discoveries in human disease. However,
renal agenesis/hypoplasia and dysplasia still represents a
challenge, both for the clinicians who attempt a precise
diagnosis and for the geneticist who tries to unravel the
genetic basis, and a better classification requires molecular
definition to be retrospectively improved. The goal appears
to be feasible with the large multicentric collaborative





Congenital abnormalities of the kidney and urinary tract are
frequently observed in the first year of life, when they
collectively represent a significant cause of morbidity [1]
and mortality. Data from birth defects registries [Metropol-
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indicate an overall frequency from three to six per 1,000
births, and the abnormalities seriously impact life expectan-
cy (http://www.marchofdimes.com). Human urinary tract
abnormalities are phenotypically variable and may affect
several segments simultaneously, often aggregating to form
complex phenotypes. Hence, clinical classification and
diagnosis may be difficult. As a consequence of the overlap
between anatomical defects, many investigators have opted
to group renal and urologic malformations under the single
label of Congenital Anomalies of the Kidney and Urinary
Tract (CAKUT) [3]. This broad classification is supported
by the fact that a mutation in a single gene can have
pleiotropic effects on the development of the urogenital
tract. For example, mutations in the PAX2 gene cause the
renal-coloboma syndrome, but the clinical features of the
trait vary significantly between affected individuals, ranging
from renal agenesis/hypoplasia to vesicoureteral reflux
(VUR) and secondary obstruction [4]. Conversely, muta-
tions in different genes can result in similar renal pheno-
types, e.g., EYA1 and PAX2 mutations both can cause the
development of hypoplastic kidneys [5]. Hence, improved
classification of urinary tract malformations may require
understanding of primary molecular defects. A broad but
clinically useful diagnostic scheme consists of classifying
malformations depending on whether the kidney, the
collecting system, or both are affected. This scheme stems
from the fact that the upper tract (glomeruli and tubules) is
derived from the metanephric mesenchyme (MM), and the
lower urinary tract (collecting duct, renal pelvis, ureter) is
derived from the ureteric bud [1]. Even if this is in contrast
with more recent data about the reciprocal interaction
between the ureteric bud and the MM (see below), this
classification can be clinically useful to partition patients
with different types of urinary tract abnormalities. In this
review, we focus on the malformations that primarily
involve a reduction of renal parenchyma in the form of
renal agenesis and/or hypoplasia/dysplasia, occurring both
as isolated forms or in association with other malformations
of the lower urinary tract (see below).
Primary renal agenesis
Bilateral renal agenesis is a rare and fatal event, usually
associated with severe oligohydramnios, which produces a
characteristic clinical pattern with facial compression and
pulmonary hypoplasia (Potter syndrome). An estimate of the
incidence of bilateral agenesis is 0.1/1000 births. Unilateral
renal agenesis is more common, although the frequency is
difficult to estimate, as it is usually clinically silent and is
commonly detected as a chance observation by autopsy or
by prenatal ultrasound [6].
Primary renal hypoplasia and dysplasia
Strictly speaking, renal hypoplasia is defined as a small
kidney, which contains intact nephrons that are reduced in
number, whereas a dysplastic kidney contains disorganized
elements and maldifferentiated tissue. Noninvasive imaging
studies such as ultrasounds and dimercaptosuccinic acid
(DMSA) scan offer limited information to help distinguish
a hypoplastic kidney from a dysplastic one. Unequivocal
distinction between these two entities therefore depends on
histological examination of renal tissue obtained from
kidney biopsy or surgical nephrectomy, which are rarely
performed. A further confounding factor is the reduction of
kidney size due to chronic injury and scarring from VUR.
Most of the time, a DMSA scan helps differentiate primary
hypoplasia or dysplasia from small kidneys secondary to
VUR. However, a DMSA scan has a low negative
predictive value in distinguishing primary hypoplasia or
dysplasia from a secondary reduction in kidney size from
VUR when scars or areas of negative isotope uptake are
present. In practice, the diagnosis of primary renal
hypoplasia is favored when the following criteria are
satisfied: (a) a reduction of renal size by 2 standard
deviations (SDS) from the mean size for the age, (b)
exclusion of renal scarring by DMSA scan, and (c) a
presence of compensatory hypertrophy of the contralateral
kidney. In all cases, the exclusion of renal cysts by
ultrasonography is mandatory to avoid confusion with
primary renal hypoplasia associated with fibrosis and cysts,
nephronophthisis being the most pertinent example. The
presence of VUR and/or ureteropelvic junction obstruction
(UPJO) does not automatically exclude the diagnosis of
hypoplasia, as both conditions are frequently associated
with primary renal-size defects. It is clear that this problem
is difficult to resolve if the ureteral defect presents
ipsilateral to renal hypoplasia. For example, severe antena-
tal hydronephrosis due to UPJO can determine the
involution of the renal parenchyma and lead to an
erroneous diagnosis of primary renal agenesis after birth.
In bilateral cases, syndromic traits as well as inherited
disorders such as medullary cystic kidney disease/nephron-
ophthisis have to be excluded. Unequivocal exclusion of
renal dysplasia is usually not feasible except in rare cases for
which histology is available. It is possible that in the near
future, molecular genetic advances could modify our present
understanding and allow for a more direct separation of the
two pathological entities based on laboratory tests.
These challenges in clinical diagnosis of renal hypopla-
sia complicate studies attempting to discover new genes
underlying this anomaly. For research purposes, we utilize a
tentative classification scheme for categorizing our subjects
for genetic studies: (1) isolated bilateral hypoplasia/dyspla-
sia, (2) isolated unilateral hypoplasia/dysplasia, and (3)
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ities such as VUR or UPJO. Once the genetic basis of
different subsets of urinary tract malformations is identified,
the classification will likely be retrospectively changed and
improved.
Kidney development and mouse models
The development of mammalian kidney derives from
reciprocally inductive events between two tissue compart-
ments of the embryonic metanephros: the ureteric bud
(UB), an outgrowth of the nephric duct, and the MM. The
ureteric bud invades the metanephric blastema at embryonic
day 10.5–11 in the mouse and 35–37 in humans. The MM
induces the ureteric bud to grow and branch while the
ureteric bud induces the MM to transdifferentiate and form
the nephrons’ epithelia (see recent reviews in kidney
development in human and mice [7, 8]).
In recent years, many factors, specific for either the UB
or the MM, have been demonstrated to induce and regulate
the epithelial conversion in the mesenchymal cells and the
UB branching, leading to the development of the final
structure and function of the kidney. Most data constituting
the basis of our current knowledge on the topic are based
on gene targeting studies in mice (Table 1). A partial list of
genes includes protooncogenes RET and Wingless-related
11 (WNT11) that are well recognized UB-specific mole-
cules, whereas glial cell-line-derived neurotrophic factor
(GDNF), Wilms tumor 1 (WT1), and Eyes absent 1 (EYA1)
represent important examples of MM-specific factors. The
paired-box gene 2 (PAX2) appears to be expressed in both
structures during kidney development [7, 9]. It is notewor-
thy that almost half of the genes on the list are
transcriptional factors or encode for proteins that are
involved in the mesenchymal to epithelial conversion.
GDNF signaling through the RET receptor is one of the
best studied pathways, representing a critical step in the
normal growth and branching of the UB during kidney
development [10]. Perturbation of Gdnf/Ret signaling has
been shown to be the downstream mechanism underlying
impaired nephrogenesis in many other mutant models (e.g.,
in Gdf11 and Six1 null mice). Numerous factors other than
the Gdnf/Ret pathway also participate in kidney and
urologic development (e.g. Wnt signaling), as evidenced
by the long list of mutant mice with malformations in the
kidney and urologic tract (Table 1).
The interdependence between developmental pathways
explains why defects in different genes result in similar
phenotypes and why morphologic classification of abnormal-
Table 1 Principal genes targeted in mice leading to renal agenesis, hypoplasia, dysplasia
Gene Human homolog Kidney phenotype Reference
Foxd1 FOXD1 Small, fused, undifferentiated kidneys Hatini et al. [59]
Eya1 EYA1 Absent kidneys Johnson et al. [60]
Xu et al. [61]
Emx2 EMX2 Absent kidneys Miyamoto et al. [62]
Hoxa11/Hoxd11 HOXA11/HOXD11 Small or absent kidneys Davis et al. [63]
Lhx1 LHX1 Absent kidneys Shawlot and Behringer [64]
Pax2 PAX2 Small or absent kidneys Torres et al. [65]
Wt1 WT1 Absent kidneys Kreidberg et al. [66]
Agtr2 AGTR2 Multiple urinary tract malformations Nishimura et al. [67]
Bmp4 BMP4 Altered ureteric bud (UB) branching Miyazaki et al. [68]
Bmp7 BMP7 Disrupted nephrogenesis Dudley et al. [69]
Wnt4 WNT4 Undifferentiated kidneys Stark et al. [70]
Ret RET Absent kidneys, severe dysgenesis Schuchardt et al. [71]
Gdnf GDNF Absent kidneys, severe dysgenesis Sanchez et al. [72]
Moore et al. [73]
Pichel et al. [74]
Six1 SIX1 Absent kidneys Xu et al. [75]
Six2 SIX2 Small kidneys Self et al. [76]
Sall1 SALL1 Absent kidneys Nishinakamura et al. [77]
Fgfr1/Fgfr2 FGFR1/FGFR2 Absent kidneys Poladia et al. [78]
Slit3 SLIT3 Small or absent kidneys Liu et al. [79]
Pbx1 PBX1 Small or absent kidneys Schnabel et al. [80]
Fgf8 FGF8 Small kidneys Perantoni et al. [81]
Rara/Rarb2 RARA/RARB2 Small kidneys Mendelsohn et al. [82]
Lim1 LIM1 Absent kidneys Kobayashi et al. [83]
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defects. Available data thus suggest a large list of candidate
genes for human renal and urologic malformations, highlight-
ing the potential for genetic heterogeneity of the trait.
Genetic contribution to human renal agenesis/
hypoplasia and dysplasia
A genetic contribution to the development of renal
hypoplasia/dysplasia has been recognized for many years.
For the isolated, nonsyndromic renal agenesis/hypoplasia
and dysplasia, only segregation studies have been per-
formed, and no loci and/or genes have been mapped so far.
Much more is known about rare syndromic forms, for
which several genes have been already implicated.
Syndromic forms
Syndromic forms of renal hypoplasia/dysplasia include rare
disorders affecting extrarenal organs such as the eye, the
central nervous system, the skin, the limbs, and others. The
list of syndromes that include the renal agenesis/hypoplasia/
dysplasia phenotype consists of at least 73 clinical
conditions (for more details, see Limwongse and Cassidy
[11]). Several genes underlying these defects having been
identified (Table 2). Renal-coloboma syndrome, orofacio-
digital syndrome, branchiootorenal syndrome, renal cysts
and diabetes syndrome, and Fraser syndrome are the most
frequent syndromes associated with renal parenchymal
defects. It seems clinically relevant that the renal abnor-
malities may represent the first manifestation of the disease,
thus requiring a detailed evaluation of other organs. A list
of extrarenal signs and symptoms that clinicians should
look for to define these syndromes include retinal coloboma
[4], deafness, external ear abnormalities including cysts and
fistulas [12, 13], anus imperforates and limb and ear
anomalies [14], diabetes and renal cystic dysplasia [15],
and others. Finally, renal agenesis/hypoplasia is frequently
part of chromosomal disorders (Table 3) that must be
recognized for genetic counseling. Most common syn-
dromes that should be considered in the initial differential
diagnosis are listed in Tables 2 and 3, and we suggest
referring to popular Web sites for further details (links
provided at the end).
Table 2 List of human malformation syndromes with kidney hypoplasia/dysplasia
Gene Human syndrome Kidney phenotype OMIM
JAG1, NOTCH2 Alagille syndrome MCDK, kidney dysplasia, kidney mesangiolipidosis #118450
#610205
BBS1-BBS11 Bardet-Biedl syndrome Renal dysplasia and calyceal malformations #209900
EYA1, SIX1, SIX2 Branchiootorenal syndrome Renal agenesis/dysplasia #113650
SOX9 Campomelic dysplasia Diverse renal malformations #114290
CHD7 CHARGE syndrome Diverse urinary tract malformations #214800
Del. 22q11 Di George syndrome Renal agenesis, dysplasia, VUR #188400
GATA3 Hypothyroidism, sensorial deafness, renal
anomalies (HDR)
Renal agenesis, dysplasia, VUR #146255
DNA repair Fanconi anemia Renal agenesis #227650
FRAS1, FREM2 Fraser syndrome Renal agenesis, dysplasia #219000
KALL1, FGFR1 Kallman’s syndrome Renal agenesis, dysplasia #308700, #147950
PAX2 Renal coloboma syndrome Renal hypoplasia, MCDK, VUR #120330
TCF2 Renal cysts and diabetes syndrome Renal dysplasia, cysts #137920
GPC3 Simpson-Golabi-Behmel syndrome Renal dysplasia, cysts #300209
DHCR7 Smith-Lemli-Opitz syndrome Renal dysplasia, cysts #270400
SALL1 Townes-Brocks syndrome Renal dysplasia, lower urinary tract malformations #107480
LMX1B Nail-patella syndrome Glomerulus malformation, renal agenesis #161200
NIPBL Cornelia de Lange syndrome Renal dysplasia #122470
CREBBP Rubinstein-Taybi syndrome Renal agenesis #180849
WNT4 Rokitansky syndrome Renal agenesis #277000
PEX-family Zellweger syndrome Renal dysplasia, cysts #214100
GLI3 Pallister-Hall syndrome Renal agenesis, dysplasia #146510
p57(KIP2) Beckwith-Wiedemann syndrome Renal dysplasia #130650
SALL4 Okihiro syndrome Renal ectopia with or without fusion,
lower urinary tract malformations
#607323
TBX3 Ulnar-Mammary syndrome Renal agenesis #181450
MCDK multicystic dysplastic kidney, VUR vesicoureteral reflux
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It is well known that nonsyndromic renal malformations
may occur as hereditary traits and can present with familial
aggregation. Evidence in favor of a genetic determination
of the disease is raised by an increased recurrence risk
among first-degree relatives and by several reports of
familial occurrence of multiple malformations, including
renal agenesis/hypoplasia and dysplasia. The relative
recurrence risk of bilateral and unilateral agenesis has been
estimated at 4–9% [6, 16, 17]. For familial cases, in most of
the pedigrees, the suggested mode of inheritance was
autosomal dominant with reduced penetrance, estimated to
range between 50% and 90% [16]. For example, a large
pedigree with an autosomal dominant mode form of
nonsyndromic renal hypoplasia and dysplasia has recently
been described [18]. However, a Somalian kindred in which
the trait was segregating in an autosomal recessive fashion
has been reported [19]. Nevertheless, until recently, no
linkage studies in familial renal agenesis/hypoplasia and
dysplasia have been reported. Incomplete penetrance,
variable expression and the fact that anatomical defects in
many family members can be clinically silent, complicate
recruitment of large pedigrees that would be suitable for
linkage analysis.
Strategies for gene discovery
Strategies to find genes causing renal agenesis/hypoplasia
and dysplasia vary significantly depending on the charac-
teristics of the study population available. Different data
sets of patients have potential advantages and possible
pitfalls.
Candidate gene studies
So far, candidate gene studies have been the only
alternative to linkage analysis to find genes underlying
both Mendelian and complex traits. Such studies have
identified many genes causing rare genetic diseases [20]
(The Human Gene Mutation Database, http://www.hgmd.
cf.ac.uk/ac/index.php) and most of the genes that are
known contribute to susceptibility to common diseases
[21, 22]. Large cohorts of sporadic cases or small
pedigrees can be utilized in case-control association
studies to find common disease associated alleles. Such
cohorts can also be screened by resequencing of candidate
genes to detect rare variants with large effects that account
for disease in a small proportion of the patients. Selection
of one approach over the other depends on the expected
degree of genetic and allelic heterogeneity of the trait
under investigation. Genetic heterogeneity refers to the
situation where mutations in different genes account for
disease in different affected individuals. Allelic heteroge-
neity refers to the presence of many independent mutations
in a given gene. For a trait with high locus and allelic
heterogeneity, the search for common disease-contributing
alleles is problematic, and resources would be better
directed toward comprehensive resequencing of candidate
genes to discovery the rare disease-causing variants. In
practice, the heterogeneity parameters are difficult to
predict a priori. The resequencing approach has been
successfully applied to find several genes causing kidney
developmental disorders. As an example, mutations in the
uroplakin III gene, which produce VUR in mice [23],
explain a small fraction of human renal hypodysplasia [24–
28]. Similarly, results from the ESCAPE study recently
provided the first comprehensive analysis of renal devel-
opmental genes in children affected by nonsyndromic renal
hypodysplasia, showing a fairly high prevalence of PAX2
and TCF2 mutations [5, 29]. Another success of the
candidate gene approach is the latest discovery of
mutations in genes of the renin-angiotensin system (RAS)
in severe forms of renal tubular dysgenesis [30]. The
search for common variants predisposing to nonsyndromic
renal hypodysplasia has not been frequently applied.
However, these common predisposing alleles may not be
recognized until a comprehensive search is undertaken. As
an example, a common noncoding variant in a RET
Table 3 Common chromosomal disorders associated with urinary tract anomalies
Chromosomal disorders Renal agenesis Hypoplasia Other associated anomalies
Patau syndrome (trisomy 13) + Holoprosencephaly, midline anomalies, cleft lip/palate
Miller-Dieker syndrome (17p13 deletion) + MR, lissencephaly, microgyria, agyria, typical facie, seizures
Edward syndrome (trisomy 18) 18q deletion + IUGR, CHD, clenched hands, rocker bottom feet SS, MR,
microcephaly, narrow external ear canals, long hands
Down syndrome (trisomy 21) + MR, hypotonia, CHD, typical face, clinodactyly
Cateye syndrome (tetrasomy 22p) + MR, CHD, colobomas, anal/digital anomalies
Velocardiofacial syndrome (22q11 deletion) + + Conotruncal CHD, thymic aplasia, typical face, cleft palate
Turner syndrome (45,X or 46,X,i(Xq)) + + SS, amenorrhea, webbed neck, cubitus valgus, hypogonadism
MR mental retardation, IUGR intrauterine growth retardation, CHD congenital heart disease, SS short stature
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for Hirschsprung disease, explaining the paucity of coding
mutations found in families showing linkage to the RET
locus [31].
Traditional linkage studies and genetic isolates
The genome-wide linkage analysis/positional cloning ap-
proach is a time-tested method used to identify disease-
causing mutations, and it has been extremely successful in
the past few decades for mapping genes that underlie
monogenic Mendelian diseases [32, 33]. This approach
hinges on availability of single, uniquely large pedigrees
that segregate genes with large effect or a large number of
small-sized pedigrees. Mutations in genes underlying
Mendelian forms of disease usually account for a fraction
of sporadic forms (e.g. PAX2 and TCF2).
For renal agenesis/hypoplasia and dysplasia, large
pedigrees amenable for linkage analysis are very difficult
to ascertain because these traits have incomplete penetrance
(due to genetic and environmental modifiers). Moreover,
many malformations, such as unilateral agenesis can be
clinically silent and will not be detected without systematic
screening of family members. As for candidate gene
studies, locus heterogeneity is another potentially compli-
cating factor that may dilute the power of linkage studies.
Our previous data demonstrated that in the setting of
reduced penetrance, variable expressivity, and very high
genetic heterogeneity, approaches based on a limited
number of uniquely large pedigrees or a very large number
of medium-sized kindreds, are more likely to be successful
to map a disease gene [34]. As a result of these difficulties,
no linkage studies of renal agenesis/hypoplasia have been
published so far. These kinds of patient cohorts are very
arduous to collect and require multicenter collaborative
efforts. We have been able to collect seven multigenera-
tional extended pedigrees segregating congenital anomalies
of the kidney and urinary tract, including renal agenesis/
hypoplasia, as an autosomal dominant trait with reduced
penetrance trait. These families allowed us to localize a
gene for this trait to a ~7 Mb interval to chromosome 1p32–
33 in a setting of genetic heterogeneity [35]. This work
represents the first step toward the discovery of a new gene
and, possibly, a new pathway, in kidney development.
Genetic isolates represent a population structure that can
greatly facilitate gene identification efforts. The genetic
isolates are populations that are originated from a limited
group of founders with little subsequent immigration into
the population. Without an inflow of genes, a long period of
time would be required for spontaneous mutations to
rebuild genetic diversity. Therefore, genetic isolates are
likely to harbor few disease-contributing alleles that have
been inherited identical by descent from common ancestors
[36–38]. These ancestral mutations can be detected by
searching for a shared haplotype signature in affected
individuals, representing a powerful shortcut to narrow
down a linkage interval to a handful of genes. This strategy,
called linkage disequilibrium (LD) mapping, has allowed
the identification of several genes for Mendelian disorders
[39–41]. Hence, the advantages of studying a genetic
isolate rely on: (a) a higher prevalence of certain diseases,
allowing traits with reduced penetrance to express and
show their hereditary component, (b) a more uniform
genetic background, thus reducing the genetic heterogene-
ity, (c) usually good genealogical records, (d) a more
uniform environment, and (e) the possibility of speeding up
gene discovery through linkage disequilibrium mapping.
We have recently characterized a genetic isolate in an
Italian valley, in which different glomerular diseases
occurred at a much higher prevalence compared with the
general population, in apparently unrelated individuals. The
genealogical reconstruction allowed us to reconnect most of
the patients to a few founders up to the sixteenth century
[42]. This study is an example of how an isolate can allow
traits that display reduced penetrance and variable expres-
sivity to express their genetic component and represent a
first step to find genes causing or predisposing to such
diseases. Further investigation of recognized population
isolates for developmental disorders, especially renal
agenesis/hypoplasia and dysplasia, might help to accelerate
gene mapping.
Genome-wide association studies
The genome-wide association study is an approach aimed at
exhaustively covering the genome to look for causative
variants. Similar to genome-wide linkage studies, no
assumptions are made about either the location of the
causative variant or the biological role of the disease gene.
Therefore, this approach represents an unbiased method to
find disease-causing genes, with also a very high probabil-
ity of discovering new genes, thus unraveling new
pathophysiological pathways. Genome-wide association
studies were not feasible until now because of the lack of
information about the variability in the human genome and
lack of low-cost, high-throughput genotyping technology.
This situation has changed in the past 2 years: dbSNP
(http://www.ncbi.nlm.nih.gov/projects/SNP/) now contains
about 5 million SNPs, including most of the SNPs with a
minor allele frequency higher than 1% estimated to exist in
the human genome [43]. Moreover, the HapMap project
[44] represents a fundamental advance to performing
efficient and successful genome-wide studies through the
determination of LD patterns and haplotype blocks across
the genome. Another important step has been the tremen-
dous improvement in genotyping technology, with the
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cost SNPs genotyping. Such platforms allow the simulta-
neous genotyping of 100–500,000 SNPs in a single assay,
allowing a dense coverage of the human genome [45, 46].
Some examples of success of this approach have been
recently published. For example, genome-wide association
studies on patients affected by age-related macular degen-
eration allowed the individuation of a common variant in
the complement factor H as a major risk-associated allele
[47, 48]. Similarly, polymorphisms in the transcription
factor TCF7L2 have been found to confer risk to type 2
diabetes in different populations [49, 50]. Whether genome-
wide association studies will lead to significant discoveries
in renal agenesis/hypoplasia and dysplasia is still unclear,
but certainly, this approach represents a very promising
strategy to identify common variants conferring suscepti-
bility to more frequent, complex traits.
Search for structural variations in the genome
A number of urogenital malformations are associated with
chromosomal abnormalities. For example, a deletion on
chromosome 10q26 has been implicated in urogenital
development [51]. Similarly, two distinct loci for renal
malformations, including VUR, have been mapped to
chromosome 13q by deletion mapping using microsatellites
in a limited number of affected individuals [52, 53].
Advances in technology, mainly, genome-scanning array
technologies and comparative DNA-sequence analyses,
have identified a high prevalence of DNA variations that
involve segments that are smaller than those recognized by
standard cytogenetics techniques [54]. These structural
variations are a common feature of our genomic landscape,
encompassing deletions, duplications, inversions, and trans-
locations, which range from a few bases up to hundreds of
kilobases. These rearrangements comprise benign poly-
morphisms, as well as deleterious mutations that can disrupt
gene structure or affect gene regulation. Newer techniques
now allow for the identification of structural variation at the
genome-wide level, enabling examination of single patients
to rapidly define a chromosomal region (locus) of interest.
Several studies have already reported structural variations
associated to human disease, leading in some cases to a
molecular definition of a disorder before a recognized
clinical syndrome [55–57].
These technologies have also been already successfully
applied to developmental disorders. A genome-wide search
for structural variations using comparative genomic hybrid-
ization (CGH) array allowed the discovery of the gene
CHD7 as a cause of CHARGE syndrome, a rare, complex
disorder in which congenital anomalies affect in a nonran-
dom fashion several tissues, including the urinary tract [58].
Careful clinical selection of patients and application of
genome-wide methods for searching structural variation in
renal agenesis/hypoplasia and dysplasia can help find new
loci linked to the disease, confirm and narrow loci obtained
by linkage analysis, and speed up the discovery of
causative genes.
Conclusions
Renal agenesis/hypoplasia and dysplasia still represents a
challenge for both the clinicians who attempt a precise
diagnosis and for the geneticists who try to unravel the
genetic basis. Genetic and clinical approaches are now
converging toward a common goal, which is the discovery
of genetic markers, to make the diagnosis of this trait easier.
The final objective is to improve classification, to make a
reliable prognosis, and to attempt prevention. Based on
advances from the last few years, the goal appears to be
more feasible with large multicentric collaborative groups
that share the same objectives and resources.
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